The DOI matches its Crossref record; 163 of the 163 references it cites were found in a registry or an index.
Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Baritaki, S., Katsman, A., Chatterjee, D., Yeung, K. C., Spandidos, D. A., & Bonavida, B. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.8.5441 · Cited by 99
RetractedTargeting RAS signalling pathways in cancer therapy
Downward, J. (2003) · Nature Reviews Cancer · doi:10.1038/nrc969 · Cited by 3,256
Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance
McCubrey, J. A., Steelman, L. S., Chappell, W. H., Abrams, S. L., Wong, E. W. T., Chang, F., Lehmann, B., Terrian, D. M., Milella, M., Tafuri, A., et al. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2006.10.001 · Cited by 2,284
Self-citationRAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
Poulikakos, P. I., Zhang, C., Bollag, G., Shokat, K. M., & Rosen, N. (2010) · Nature · doi:10.1038/nature08902 · Cited by 1,811
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
Hatzivassiliou, G., Song, K., Yen, I., Brandhuber, B. J., Anderson, D. J., Alvarado, R., Ludlam, M. J. C., Stokoe, D., Gloor, S. L., Vigers, G., et al. (2010) · Nature · doi:10.1038/nature08833 · Cited by 1,622
Shah, N. P., Nicoll, J. M., Nagar, B., Gorre, M. E., Paquette, R. L., Kuriyan, J., & Sawyers, C. L. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00096-x · Cited by 1,612
Independent Human MAP-Kinase Signal Transduction Pathways Defined by MEK and MKK Isoforms
Dérijard, B., Raingeaud, J., Barrett, T., Wu, I.-H., Han, J., Ulevitch, R. J., & Davis, R. J. (1995) · Science · doi:10.1126/science.7839144 · Cited by 1,555
Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
Heidorn, S. J., Milagre, C., Whittaker, S., Nourry, A., Niculescu-Duvas, I., Dhomen, N., Hussain, J., Reis-Filho, J. S., Springer, C. J., Pritchard, C., et al. (2010) · Cell · doi:10.1016/j.cell.2009.12.040 · Cited by 1,465
Coupling of the RAS-MAPK Pathway to Gene Activation by RSK2, a Growth Factor-Regulated CREB Kinase
Xing, J., Ginty, D. D., & Greenberg, M. E. (1996) · Science · doi:10.1126/science.273.5277.959 · Cited by 1,248
The emerging roles of forkhead box (Fox) proteins in cancer
Myatt, S. S., & Lam, E. W. F. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2223 · Cited by 1,070
Coordinating ERK/MAPK signalling through scaffolds and inhibitors
Kolch, W. (2005) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1743 · Cited by 1,070
JNK phosphorylation of Bim-related members of the Bcl2 family induces Bax-dependent apoptosis
Lei, K., & Davis, R. J. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0438011100 · Cited by 1,068
Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy
Wendel, H.-G., Stanchina, E. D., Fridman, J. S., Malina, A., Ray, S., Kogan, S., Cordon-Cardo, C., Pelletier, J., & Lowe, S. W. (2004) · Nature · doi:10.1038/nature02369 · Cited by 951
Mitogen-activated protein kinases activate the serine/threonine kinases Mnk1 and Mnk2
Waskiewicz, A. J. (1997) · The EMBO Journal · doi:10.1093/emboj/16.8.1909 · Cited by 947
Lin, A. W., Barradas, M., Stone, J. C., van Aelst, L., Serrano, M., & Lowe, S. W. (1998) · Genes & Development · doi:10.1101/gad.12.19.3008 · Cited by 945
Suppression of Raf-1 kinase activity and MAP kinase signalling by RKIP
Yeung, K., Seitz, T., Li, S., Janosch, P., McFerran, B., Kaiser, C., Fee, F., Katsanakis, K. D., Rose, D. W., Mischak, H., et al. (1999) · Nature · doi:10.1038/43686 · Cited by 893
Reactive Oxygen Species-Induced Activation of the MAP Kinase Signaling Pathways
McCubrey, J. A., LaHair, M. M., & Franklin, R. A. (2006) · Antioxidants & Redox Signaling · doi:10.1089/ars.2006.8.1775 · Cited by 803
Self-citationRoux, P. P., Shahbazian, D., Vu, H., Holz, M. K., Cohen, M. S., Taunton, J., Sonenberg, N., & Blenis, J. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m700906200 · Cited by 702
MEK1 mutations confer resistance to MEK and B-RAF inhibition
Emery, C. M., Vijayendran, K. G., Zipser, M. C., Sawyer, A. M., Niu, L., Kim, J. J., Hatton, C., Chopra, R., Oberholzer, P. A., Karpova, M. B., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905833106 · Cited by 633
Regulation of Raf-1 by Direct Feedback Phosphorylation
Dougherty, M. K., Müller, J., Ritt, D. A., Zhou, M., Zhou, X. Z., Copeland, T. D., Conrads, T. P., Veenstra, T. D., Lu, K. P., & Morrison, D. K. (2005) · Molecular Cell · doi:10.1016/j.molcel.2004.11.055 · Cited by 633
Ohren, J. F., Chen, H., Pavlovsky, A., Whitehead, C., Zhang, E., Kuffa, P., Yan, C., McConnell, P., Spessard, C., Banotai, C., et al. (2004) · Nature Structural & Molecular Biology · doi:10.1038/nsmb859 · Cited by 626
Pratilas, C. A., Taylor, B. S., Ye, Q., Viale, A., Sander, C., Solit, D. B., & Rosen, N. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0900780106 · Cited by 614
Ras recruits Raf-1 to the plasma membrane for activation by tyrosine phosphorylation.
Marais, R., Light, Y., Paterson, H. F., & Marshall, C. J. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb07316.x · Cited by 612
Moerke, N. J., Aktas, H., Chen, H., Cantel, S., Reibarkh, M. Y., Fahmy, A., Gross, J. D., Degterev, A., Yuan, J., Chorev, M., et al. (2007) · Cell · doi:10.1016/j.cell.2006.11.046 · Cited by 572
The mTOR/PI3K and MAPK pathways converge on eIF4B to control its phosphorylation and activity
Shahbazian, D., Roux, P. P., Mieulet, V., Cohen, M. S., Raught, B., Taunton, J., Hershey, J. W., Blenis, J., Pende, M., & Sonenberg, N. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7601166 · Cited by 531
The Bone Marrow Microenvironment as a Tumor Sanctuary and Contributor to Drug Resistance
Meads, M. B., Hazlehurst, L. A., & Dalton, W. S. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-2223 · Cited by 520
Elevated CRAF as a Potential Mechanism of Acquired Resistance to BRAF Inhibition in Melanoma
Montagut, C., Sharma, S. V., Shioda, T., McDermott, U., Ulman, M., Ulkus, L. E., Dias-Santagata, D., Stubbs, H., Lee, D. Y., Singh, A., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6787 · Cited by 508
Ueda, T., Watanabe-Fukunaga, R., Fukuyama, H., Nagata, S., & Fukunaga, R. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.15.6539-6549.2004 · Cited by 507
Dissecting eIF4E action in tumorigenesis
Wendel, H.-G., Silva, R. L. A., Malina, A., Mills, J. R., Zhu, H., Ueda, T., Watanabe-Fukunaga, R., Fukunaga, R., Teruya-Feldstein, J., Pelletier, J., et al. (2007) · Genes & Development · doi:10.1101/gad.1604407 · Cited by 487
MP1: A MEK Binding Partner That Enhances Enzymatic Activation of the MAP Kinase Cascade
Schaeffer, H. J., Catling, A. D., Eblen, S. T., Collier, L. S., Krauss, A., & Weber, M. J. (1998) · Science · doi:10.1126/science.281.5383.1668 · Cited by 471
Waskiewicz, A. J., Johnson, J. C., Penn, B., Mahalingam, M., Kimball, S. R., & Cooper, J. A. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.3.1871 · Cited by 469
Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma
Palanisamy, N., Ateeq, B., Kalyana-Sundaram, S., Pflueger, D., Ramnarayanan, K., Shankar, S., Han, B., Cao, Q., Cao, X., Suleman, K., et al. (2010) · Nature Medicine · doi:10.1038/nm.2166 · Cited by 464
Serine and tyrosine phosphorylations cooperate in Raf-1, but not B-Raf activation
Mason, C. S. (1999) · The EMBO Journal · doi:10.1093/emboj/18.8.2137 · Cited by 457
Differential Regulation of Raf-1, A-Raf, and B-Raf by Oncogenic Ras and Tyrosine Kinases
Marais, R., Light, Y., Paterson, H. F., Mason, C. S., & Marshall, C. J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.7.4378 · Cited by 456
Joseph, E. W., Pratilas, C. A., Poulikakos, P. I., Tadi, M., Wang, W., Taylor, B. S., Halilovic, E., Persaud, Y., Xing, F., Viale, A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1008990107 · Cited by 449
Transcriptional regulation by MAP kinases
Davis, R. J. (1995) · Molecular Reproduction and Development · doi:10.1002/mrd.1080420414 · Cited by 429
The MCL-1 BH3 helix is an exclusive MCL-1 inhibitor and apoptosis sensitizer
Stewart, M. L., Fire, E., Keating, A. E., & Walensky, L. D. (2010) · Nature Chemical Biology · doi:10.1038/nchembio.391 · Cited by 418
Wilson, B. E., Mochon, E., & Boxer, L. M. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.10.5546 · Cited by 410
She, Q.-B., Halilovic, E., Ye, Q., Zhen, W., Shirasawa, S., Sasazuki, T., Solit, D. B., & Rosen, N. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.05.023 · Cited by 400
Yeung, K., Janosch, P., McFerran, B., Rose, D. W., Mischak, H., Sedivy, J. M., & Kolch, W. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.9.3079-3085.2000 · Cited by 389
Yeung, K. C., Rose, D. W., Dhillon, A. S., Yaros, D., Gustafsson, M., Chatterjee, D., McFerran, B., Wyche, J., Kolch, W., & Sedivy, J. M. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.21.7207-7217.2001 · Cited by 387
Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia
Steelman, L. S., Abrams, S. L., Whelan, J., Bertrand, F. E., Ludwig, D. E., Bäsecke, J., Libra, M., Stivala, F., Milella, M., Tafuri, A., et al. (2008) · Leukemia · doi:10.1038/leu.2008.26 · Cited by 385
Self-citationCorbit, K. C., Trakul, N., Eves, E. M., Diaz, B., Marshall, M., & Rosner, M. R. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210015200 · Cited by 360
Di Nicolantonio, F., Arena, S., Tabernero, J., Grosso, S., Molinari, F., Macarulla, T., Russo, M., Cancelliere, C., Zecchin, D., Mazzucchelli, L., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci37539 · Cited by 343
Bone marrow microenvironment and the identification of new targets for myeloma therapy
Podar, K., Chauhan, D., & Anderson, K. C. (2009) · Leukemia · doi:10.1038/leu.2008.259 · Cited by 337
Kuroda, J., Puthalakath, H., Cragg, M. S., Kelly, P. N., Bouillet, P., Huang, D. C. S., Kimura, S., Ottmann, O. G., Druker, B. J., Villunger, A., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0606176103 · Cited by 336
Targeting the Eukaryotic Translation Initiation Factor 4E for Cancer Therapy
Graff, J. R., Konicek, B. W., Carter, J. H., & Marcusson, E. G. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5635 · Cited by 332
Bordeleau, M.-E., Robert, F., Gerard, B., Lindqvist, L., Chen, S. M. H., Wendel, H.-G., Brem, B., Greger, H., Lowe, S. W., Porco, J. A., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34753 · Cited by 332
Domina, A. M., Vrana, J. A., Gregory, M. A., Hann, S. R., & Craig, R. W. (2004) · Oncogene · doi:10.1038/sj.onc.1207692 · Cited by 327
Assouline, S., Culjkovic, B., Cocolakis, E., Rousseau, C., Beslu, N., Amri, A., Caplan, S., Leber, B., Roy, D.-C., Miller, W. H., et al. (2009) · Blood · doi:10.1182/blood-2009-02-205153 · Cited by 314
Regulatory phosphorylation of Bim: sorting out the ERK from the JNK
Ley, R., Ewings, K. E., Hadfield, K., & Cook, S. J. (2005) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401688 · Cited by 313
Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E–mutated melanomas
Smalley, K. S. M., Lioni, M., Palma, M. D., Xiao, M., Desai, B., Egyhazi, S., Hansson, J., Wu, H., King, A. J., Van Belle, P., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0431 · Cited by 309
Kentsis, A., Topisirovic, I., Culjkovic, B., Shao, L., & Borden, K. L. B. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0406927102 · Cited by 305
Mechanisms of drug inhibition of signalling molecules
Sebolt-Leopold, J. S., & English, J. M. (2006) · Nature · doi:10.1038/nature04874 · Cited by 304
Essafi, A., Fernández de Mattos, S., Hassen, Y. A. M., Soeiro, I., Mufti, G. J., Thomas, N. S. B., Medema, R. H., & Lam, E. W.-F. (2005) · Oncogene · doi:10.1038/sj.onc.1208421 · Cited by 293
Harada, H., Quearry, B., Ruiz-Vela, A., & Korsmeyer, S. J. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0406837101 · Cited by 287
Thomas, A., Rouby, S. E., Reed, J. C., Krajewski, S., Silber, R.-E., Potmĕsil, M., & Newcomb, E. (1996) · PubMed · Cited by 265
Paradoxical activation of Raf by a novel Raf inhibitor
Hall-Jackson, C. A., Eyers, P. A., Cohen, P., Goedert, M., Tom Boyle, F., Hewitt, N., Plant, H., & Hedge, P. (1999) · Chemistry & Biology · doi:10.1016/s1074-5521(99)80088-x · Cited by 265
Kornblau, S. M., Womble, M., Qiu, Y. H., Jackson, C. E., Chen, W., Konopleva, M., Estey, E. H., & Andreeff, M. (2006) · Blood · doi:10.1182/blood-2006-02-003475 · Cited by 265
Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)
Dry, J. R., Pavey, S., Pratilas, C. A., Harbron, C., Runswick, S., Hodgson, D., Chresta, C., McCormack, R., Byrne, N., Cockerill, M., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1577 · Cited by 262
Genetic Predictors of MEK Dependence in Non–Small Cell Lung Cancer
Pratilas, C. A., Hanrahan, A. J., Halilovic, E., Persaud, Y., Soh, J., Chitale, D., Shigematsu, H., Yamamoto, H., Sawai, A., Janakiraman, M., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-2223 · Cited by 255
Reduction of Raf-1 Kinase Inhibitor Protein Expression Correlates with Breast Cancer Metastasis
Hagan, S., Al-Mulla, F., Mallon, E., Oien, K., Ferrier, R., Gusterson, B., Curto García, J. J., & Kolch, W. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0283 · Cited by 252
Lassman, A. B., Rossi, M. R., Razier, J. R., Abrey, L. E., Lieberman, F. S., Grefe, C. N., Lamborn, K., Pao, W., Shih, A. H., Kuhn, J. G., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0421 · Cited by 252
Pepper, C., Lin, T. T., Pratt, G., Hewamana, S., Brennan, P., Hiller, L., Hills, R., Ward, R., Starczynski, J., Austen, B., et al. (2008) · Blood · doi:10.1182/blood-2008-05-157131 · Cited by 248
FLT3 mutations in childhood acute lymphoblastic leukemia
Armstrong, S. A., Mabon, M. E., Silverman, L. B., Li, A., Gribben, J. G., Fox, E. A., Sallan, S. E., & Korsmeyer, S. J. (2004) · Blood · doi:10.1182/blood-2003-07-2441 · Cited by 246
McCubrey, J. A., Steelman, L. S., Abrams, S. L., Bertrand, F. E., Ludwig, D. E., Bäsecke, J., Libra, M., Stivala, F., Milella, M., Tafuri, A., et al. (2008) · Leukemia · doi:10.1038/leu.2008.27 · Cited by 235
Self-citationEvidence That Ser87 of BimEL Is Phosphorylated by Akt and Regulates BimEL Apoptotic Function
Qi, X.-J., Wildey, G. M., & Howe, P. H. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m505546200 · Cited by 234
Genetics of therapy-related myelodysplasia and acute myeloid leukemia
Pedersen-Bjergaard, J., Andersen, M. K., Andersen, M. T., & Christiansen, D. H. (2008) · Leukemia · doi:10.1038/sj.leu.2405078 · Cited by 232
Marks, J. L., Gong, Y., Chitale, D., Golas, B., McLellan, M. D., Kasai, Y., Ding, L., Mardis, E. R., Wilson, R. K., Solit, D., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0099 · Cited by 211
Shinjyo, T., Kuribara, R., Inukai, T., Hosoi, H., Kinoshita, T., Miyajima, A., Houghton, P. J., Look, A. T., Ozawa, K., & Inaba, T. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.3.854-864.2001 · Cited by 206
Serine/threonine phosphorylation in cytokine signal transduction
McCubrey, J., May, W. S., Duronio, V, & Mufson, A. (2000) · Leukemia · doi:10.1038/sj.leu.2401657 · Cited by 206
Self-citation(2004) · Advances in Cancer Research · doi:10.1016/s0065-230x(04)91005-6 · Cited by 204
Ueda, T., Sasaki, M., Elia, A. J., Chio, I. I. C., Hamada, K., Fukunaga, R., & Mak, T. W. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1008136107 · Cited by 204
Phase I study of sorafenib in patients with refractory or relapsed acute leukemias
Borthakur, G., Kantarjian, H., Ravandi, F., Zhang, W., Konopleva, M., Wright, J. J., Faderl, S., Verstovsek, S., Mathews, S., Andreeff, M., et al. (2011) · Haematologica · doi:10.3324/haematol.2010.030452 · Cited by 202
Shin, S.-Y., Rath, O., Choo, S.-M., Fee, F., McFerran, B., Kolch, W., & Cho, K.-H. (2009) · Journal of Cell Science · doi:10.1242/jcs.036319 · Cited by 192
The role of Raf kinase inhibitor protein (RKIP) in health and disease
Keller, E. T., Fu, Z., & Brennan, M. (2004) · Biochemical Pharmacology · doi:10.1016/j.bcp.2004.04.024 · Cited by 191
Tamburini, J., Green, A. S., Bardet, V., Chapuis, N., Park, S., Willems, L., Uzunov, M., Ifrah, N., Dreyfus, F., Lacombe, C., et al. (2009) · Blood · doi:10.1182/blood-2008-10-184515 · Cited by 190
Snail is a repressor of RKIP transcription in metastatic prostate cancer cells
Beach, S., Tang, H., Park, S., Dhillon, A. S., Keller, E. T., Kolch, W., & Yeung, K. C. (2008) · Oncogene · doi:10.1038/sj.onc.1210860 · Cited by 189
New modes of translational control in development, behavior, and disease.
Sonenberg, N., & Hinnebusch, A. G. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.11.018 · Cited by 187
Targeting the leukemic stem cell: the Holy Grail of leukemia therapy
Misaghian, N., Ligresti, G., Steelman, L. S., Bertrand, F. E., Bäsecke, J., Libra, M., Nicoletti, F., Stivala, F., Milella, M., Tafuri, A., et al. (2009) · Leukemia · doi:10.1038/leu.2008.246 · Cited by 187
Self-citationTargeting the mitogen-activated protein kinase pathway: physiological feedback and drug response
Pratilas, C. A., & Solit, D. B. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-3064 · Cited by 183
SOS Phosphorylation and Disassociation of the Grb2-SOS Complex by the ERK and JNK Signaling Pathways
Chen§, D., Waters§, S. B., Holt, K. H., & Pessin, J. E. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.11.6328 · Cited by 183
A Mek1–Mek2 heterodimer determines the strength and duration of the Erk signal
Catalanotti, F., Reyes, G., Jesenberger, V., Galabova-Kovacs, G., de Matos Simoes, R., Carugo, O., & Baccarini, M. (2009) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1564 · Cited by 182
Le, D. T., Kong, N., Zhu, Y., Lauchle, J. O., Aiyigari, A., Braun, B. S., Wang, E., Kogan, S. C., Le Beau, M. M., Parada, L., et al. (2004) · Blood · doi:10.1182/blood-2003-08-2650 · Cited by 175
McCubrey, J. A., Steelman, L. S., Kempf, C. R., Chappell, W. H., Abrams, S. L., Stivala, F., Malaponte, G., Nicoletti, F., Libra, M., Bäsecke, J., et al. (2011) · Journal of Cellular Physiology · doi:10.1002/jcp.22647 · Cited by 171
Self-citationZhang, W., Konopleva, M., Ruvolo, V. R., McQueen, T., Evans, R. L., Bornmann, W. G., McCubrey, J., Cortes, J., & Andreeff, M. (2008) · Leukemia · doi:10.1038/sj.leu.2405098 · Cited by 170
Self-citationHalilovic, E., She, Q.-B., Ye, Q., Pagliarini, R., Sellers, W. R., Solit, D. B., & Rosen, N. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0409 · Cited by 168
A hidden oncogenic positive feedback loop caused by crosstalk between Wnt and ERK pathways
Kim, D., Rath, O., Kolch, W., & Cho, K.-H. (2007) · Oncogene · doi:10.1038/sj.onc.1210230 · Cited by 166
Syk-dependent mTOR activation in follicular lymphoma cells
Leseux, L., Hamdi, S. M., al Saati, T., Capilla, F., Recher, C., Laurent, G., & Bezombes, C. (2006) · Blood · doi:10.1182/blood-2006-05-026203 · Cited by 165
Conferring specificity on the ubiquitous Raf/MEK signalling pathway
O'Neill, E., & Kolch, W. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601488 · Cited by 162
Xu, S., Robbins, D. J., Frost, J. A., Dang, A., Lange, C. A., & Cobb, M. H. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.15.6808 · Cited by 157
Roles of Bim in Apoptosis of Normal and Bcr-Abl-Expressing Hematopoietic Progenitors
Kuribara, R., Honda, H., Matsui, H., Shinjyo, T., Inukai, T., Sugita, K., Nakazawa, S., Hirai, H., Ozawa, K., & Inaba, T. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.14.6172-6183.2004 · Cited by 156
Response and resistance to MEK inhibition in leukaemias initiated by hyperactive Ras
Lauchle, J., Kim, D. S., Le, D., Akagi, K., Crone, M., Krisman, K., Warner, K., Bonifas, J. M., Li, Q., Coakley, K. M., et al. (2009) · Nature · doi:10.1038/nature08279 · Cited by 154
Regulation of the Raf–MEK–ERK pathway by protein phosphatase 5
von Kriegsheim, A., Pitt, A. R., Grindlay, G. J., Kölch, W., & Dhillon, A. S. (2006) · Nature Cell Biology · doi:10.1038/ncb1465 · Cited by 151
Bacher, U., Haferlach, T., Kern, W., Haferlach, C., & Schnittger, S. (2007) · Haematologica · doi:10.3324/haematol.10869 · Cited by 150
Balakrishnan, K., Burger, J. A., Wierda, W. G., & Gandhi, V. V. (2008) · Blood · doi:10.1182/blood-2008-02-138560 · Cited by 148
Shih, L.-Y., Huang, C.-F., Wang, P.-N., Jh, W., Lin, T.-L., Dunn, P., & Kuo, M.-C. (2004) · Leukemia · doi:10.1038/sj.leu.2403274 · Cited by 145
Mutation of Genes Affecting the RAS Pathway Is Common in Childhood Acute Lymphoblastic Leukemia
Case, M. C., Matheson, E. C., Minto, L., Hassan, R., Harrison, C. J., Bown, N. P., Bailey, S., Vormoor, J. H., Hall, A. G., & Irving, J. A. E. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0101 · Cited by 138
The Raf/MEK/ERK pathway can govern drug resistance, apoptosis and sensitivity to targeted therapy
Abrams, S. L., Steelman, L. S., Shelton, J. G., Wong, E. W. T., Chappell, W. H., Bäsecke, J., Stivala, F., Donia, M., Nicoletti, F., Libra, M., et al. (2010) · Cell Cycle · doi:10.4161/cc.9.9.11483 · Cited by 137
Self-citationScheijen, B., Ngo, H. T., Kang, H. K., & Griffin, J. D. (2004) · Oncogene · doi:10.1038/sj.onc.1207456 · Cited by 128
High, L. M., Szymanska, B., Wilczynska-Kalak, U., Barber, N., O’Brien, R., Khaw, S. L., Vikstrom, I. B., Roberts, A. W., & Lock, R. B. (2009) · Molecular Pharmacology · doi:10.1124/mol.109.060780 · Cited by 126
Casar, B., Arozarena, I., Sanz-Moreno, V., Pinto, A., Agudo-Ibáñez, L., Marais, R., Lewis, R. E., Berciano, M., & Crespo, P. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.01359-08 · Cited by 126
Christiansen, D. H., Andersen, M. K., Desta, F. Z., & Pedersen-Bjergaard, J. (2005) · Leukemia · doi:10.1038/sj.leu.2404009 · Cited by 121
Bachmann, P. S., Piazza, R., Janes, M. E., Wong, N. C., Davies, C. H., Mogavero, A., Bhadri, V. A., Szymanska, B., Geninson, G., Magistroni, V., et al. (2010) · Blood · doi:10.1182/blood-2010-05-284968 · Cited by 121
Paoluzzi, L., Gönen, M., Bhagat, G., Furman, R. R., Gardner, J. R., Scotto, L., Gueorguiev, V. D., Heaney, M. L., Manova, K., & O’Connor, O. A. (2008) · Blood · doi:10.1182/blood-2007-12-130781 · Cited by 121
RAS oncogene mutations and outcome of therapy for childhood acute lymphoblastic leukemia
Perentesis, J. P., Bhatia, R., Boyle, E., Shao, Y., Shu, X., Steinbuch, M., Sather, H. N., Gaynon, P. S., Kiffmeyer, W. R., Envall-Fox, J., et al. (2004) · Leukemia · doi:10.1038/sj.leu.2403272 · Cited by 118
FLT3 inhibition and mechanisms of drug resistance in mutant FLT3-positive AML
Weisberg, E., Barrett, R., Liu, Q., Stone, R. M., Gray, N. S., & Griffin, J. D. (2009) · Drug Resistance Updates · doi:10.1016/j.drup.2009.04.001 · Cited by 116
Identification of novel ERK-mediated feedback phosphorylation sites at the C-terminus of B-Raf
Brummer, T., Naegele, H., Reth, M. G., & Misawa, Y. (2003) · Oncogene · doi:10.1038/sj.onc.1207185 · Cited by 115
Peponi, E., Drakos, E., Reyes, G. H., Leventaki, V., Rassidakis, G. Z., & Medeiros, L. J. (2006) · American Journal Of Pathology · doi:10.2353/ajpath.2006.051078 · Cited by 115
Davis, J. M., Navolanic, P. M., Oppenheimer, C. W., Steelman, L. S., Hu, W., Konopleva, M. Y., Blagosklonny, M. V., & McCubrey, J. A. (2003) · PubMed · Cited by 114
Self-citationTumorigenic activity and therapeutic inhibition of Rheb GTPasePreprint
Mavrakis, K. J., Zhu, H., Silva, R. L. A., Mills, J. R., Teruya‐Feldstein, J., Lowe, S. W., Tam, W., Pelletier, J., & Wendel, H. (2008) · Genes & Development · doi:10.1101/gad.1690808 · Cited by 113
Perspectives on inhibiting mTOR as a future treatment strategy for hematological malignancies
Chapuis, N., Tamburini, J., Green, A. S., Willems, L., Bardet, V., Park, S., Lacombe, C., Mayeux, P., & Bouscary, D. (2010) · Leukemia · doi:10.1038/leu.2010.170 · Cited by 109
Choi, S., Henderson, M. J., Kwan, E., Beesley, A. H., Sutton, R., Bahar, A. Y., Giles, J. E., Venn, N. C., Pozza, L. D., Baker, D. L., et al. (2007) · Blood · doi:10.1182/blood-2007-01-067785 · Cited by 106
Further evidence that ribavirin interacts with eIF4E
Kentsis, A., Volpon, L., Topisirović, I., Soll, C. E., Čuljković, B., Shao, L., & Borden, K. L. B. (2005) · RNA · doi:10.1261/rna.2238705 · Cited by 104
Regulation of Bcl2 Phosphorylation and Potential Significance for Leukemic Cell Chemoresistance
Deng, X., Kornblau, S. M., Ruvolo, P. P., & May, W. S. (2000) · JNCI Monographs · doi:10.1093/oxfordjournals.jncimonographs.a024254 · Cited by 103
Self-citationMathematical Modeling of the Influence of RKIP on the ERK Signaling Pathway
Kwang-Hyun, C., Shin, S., Kim, H., Olaf Wolkenhauer, A., McFerran, B. W., & Kölch, W. (2003) · Lecture notes in computer science · doi:10.1007/3-540-36481-1_11 · Cited by 101
The bone marrow microenvironment as a sanctuary for minimal residual disease in CML
Nair, R. R., Tolentino, J. H. G., & Hazlehurst, L. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.04.003 · Cited by 101
The role of Bcl-2 family proteins in chronic lymphocytic leukaemia
Buggins, A. G. S., & Pepper, C. J. (2010) · Leukemia Research · doi:10.1016/j.leukres.2010.03.011 · Cited by 101
Baritaki, S., Yeung, K. C., Palladino, M. A., Berenson, J. R., & Bonavida, B. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1069 · Cited by 101
Gillings, A. S., Balmanno, K., Wiggins, C. M., Johnson, M., & Cook, S. J. (2009) · FEBS Journal · doi:10.1111/j.1742-4658.2009.07329.x · Cited by 98
McCubrey, J. A., Steelman, L., Hoyle, P., Blalock, W. L., Oppenheimer, C. W., Franklin, R. A., Cherwinski, H. M., Bosch, E., & McMahon, M. (1998) · Leukemia · doi:10.1038/sj.leu.2401215 · Cited by 98
Self-citationStolz, C., Heß, G., Hähnel, P. S., Grabellus, F., Hoffarth, S., Schmid, K. W., & Schüler, M. (2008) · Blood · doi:10.1182/blood-2007-11-124487 · Cited by 95
Lu, Z. H., Shvartsman, M. B., Lee, A. Y., Shao, J. M., Murray, M. M., Kladney, R. D., Fan, D., Krajewski, S., Chiang, G. G., Mills, G. B., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3467 · Cited by 95
Inherited predispositions and hyperactive Ras in myeloid leukemogenesis
Lauchle, J. O., Braun, B. S., Loh, M. L., & Shannon, K. (2006) · Pediatric Blood & Cancer · doi:10.1002/pbc.20644 · Cited by 94
Balan, V., Leicht, D. T., Zhu, J., Balan, K., Kaplun, A., Singh‐Gupta, V., Qin, J., Ruan, H., Comb, M. J., & Tzivion, G. (2006) · Molecular Biology of the Cell · doi:10.1091/mbc.e04-12-1123 · Cited by 94
Drug resistance in mutant FLT3-positive AML
Weisberg, E., Sattler, M., Ray, A., & Griffin, J. D. (2010) · Oncogene · doi:10.1038/onc.2010.273 · Cited by 93
MCL-1–dependent leukemia cells are more sensitive to chemotherapy than BCL-2–dependent counterparts
Brunelle, J. K., Ryan, J. A., Yecies, D. W., Opferman, J. T., & Letai, A. G. (2009) · The Journal of Cell Biology · doi:10.1083/jcb.200904049 · Cited by 93
Zebisch, A., Staber, P. B., Delavar, A., Bodner, C., Hiden, K., Fischereder, K., Janakiraman, M., Linkesch, W., Auner, H. W., Emberger, W., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-0115 · Cited by 90
Hoyle, P., Moye, P. W., Steelman, L., Blalock, W. L., Franklin, R. A., Pearce, M., Cherwinski, H. M., Bosch, E., McMahon, M., & McCubrey, J. A. (2000) · Leukemia · doi:10.1038/sj.leu.2401720 · Cited by 89
Self-citationKuroda, J., Kimura, S. H., Andreeff, M., Ashihara, E., Kamitsuji, Y., Yokota, A., Kawata, E., Takeuchi, M., Tanaka, R., Murotani, Y., et al. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06899.x · Cited by 87
Crump, M., Hedley, D. W., Kamel‐Reid, S., Leber, B. F., Wells, R. W., Brandwein, J. M., Buckstein, R. J., Kassis, J., Minden, M. D., Matthews, J., et al. (2010) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428190903585286 · Cited by 84
IκB kinase overcomes PI3K/Akt and ERK/MAPK to control FOXO3a activity in acute myeloid leukemia
Chapuis, N., Park, S., Léotoing, L., Tamburini, J., Verdier, F., Bardet, V., Green, A. S., Willems, L., Agou, F., Ifrah, N., et al. (2010) · Blood · doi:10.1182/blood-2009-12-260711 · Cited by 82
Hazlehurst, L., Argilagos, R. F., & Dalton, W. S. (2006) · British Journal of Haematology · doi:10.1111/j.1365-2141.2006.06435.x · Cited by 82
Zimmerman, E., Dollins, C., Crawford, M., Grant, S., Nana-Sinkam, S. P., Richards, K., Hammond, S., & Graves, L. (2010) · Molecular Pharmacology · doi:10.1124/mol.110.066258 · Cited by 79
Involvement of p53 and Raf/MEK/ERK pathways in hematopoietic drug resistance
McCubrey, J. A., Abrams, S. L., Ligresti, G., Misaghian, N., Wong, E. W. T., Steelman, L. S., Bäsecke, J., Troppmair, J., Libra, M., Nicoletti, F., et al. (2008) · Leukemia · doi:10.1038/leu.2008.207 · Cited by 78
Self-citationBlalock, W. L., Pearce, M., Steelman, L. S., Franklin, R. A., McCarthy, S. A., Cherwinski, H. M., McMahon, M., & McCubrey, J. A. (2000) · Oncogene · doi:10.1038/sj.onc.1203337 · Cited by 75
Self-citationHayashi, K., Shibata, K., Morita, T., Iwasaki, K., Watanabe, M., & Sobue, K. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m405100200 · Cited by 72
Phosphatase and Feedback Regulation of Raf-1 Signaling
Dhillon, A. S., von Kriegsheim, A., Grindlay, J., & Kölch, W. (2007) · Cell Cycle · doi:10.4161/cc.6.1.3593 · Cited by 63
McCubrey, J. A., Steelman, L. S., Abrams, S. L., Chappell, W. H., Russo, S. M., Ove, R., Milella, M., Tafuri, A., Lunghi, P., Bonati, A., et al. (2010) · Expert Opinion on Emerging Drugs · doi:10.1517/14728210903282760 · Cited by 63
Self-citationMakita, Y., Narumi, Y., Yoshida, M., Niihori, T., Kure, S., Fujieda, K., Matsubara, Y., & Aoki, Y. (2007) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0b013e3180547136 · Cited by 59
Regulation of RKIP binding to the N‐region of the Raf‐1 kinase
Park, S., Rath, O., Beach, S., Xiang, X., Kelly, S. M., Luo, Z., Kölch, W., & Yeung, K. C. (2006) · FEBS Letters · doi:10.1016/j.febslet.2006.10.054 · Cited by 57
Rath, O., Park, S., Tang, H., Banfield, M. J., Brady, R. L., Lee, Y. C., Dignam, J. D., Sedivy, J. M., Kölch, W., & Yeung, K. C. (2008) · Cellular Signalling · doi:10.1016/j.cellsig.2008.01.012 · Cited by 53
Shelton, J. G., Moye, P. W., Steelman, L. S., Blalock, W. L., Lee, J. T., Franklin, R. A., McMahon, M., & McCubrey, J. A. (2003) · Leukemia · doi:10.1038/sj.leu.2403052 · Cited by 49
Self-citationActivation of the Calcium/Calmodulin-Dependent Protein Kinases as a Consequence of Oxidative Stress
Franklin, R. A., Rodriguez–Mora, O., LaHair, M. M., & McCubrey, J. A. (2006) · Antioxidants and Redox Signaling · doi:10.1089/ars.2006.8.1807 · Cited by 48
Self-citationMolecular Pathways Leading to Oxidative Stress-Induced Phosphorylation of Akt
LaHair, M. M., Howe, C. J., Rodriguez–Mora, O., et al. (2006) · Antioxidants and Redox Signaling · doi:10.1089/ars.2006.8.1749 · Cited by 47
Raf Kinase Inhibitor Protein Regulation of Raf and MAPK Signaling
Hagan, S., Garcia, R. L., Dhillon, A. S., & Kölch, W. (2006) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(05)07021-7 · Cited by 46
Mutations in the BRAF and N-ras genes in childhood acute lymphoblastic leukaemia
Gustafsson, B. M., Angelini, S., Sander, B., et al. (2004) · Leukemia · doi:10.1038/sj.leu.2403589 · Cited by 46
Steelman, L. S., Abrams, S. L., Shelton, J. G., Chappell, W. H., Bäsecke, J., Stivala, F., Donia, M., Nicoletti, F., Libra, M., Martelli, A. M., et al. (2010) · Cell Cycle · doi:10.4161/cc.9.8.11487 · Cited by 46
Self-citationBlalock, W. L., Moye, P. W., Chang, F., Pearce, M., Steelman, L., McMahon, M., & McCubrey, J. A. (2000) · Leukemia · doi:10.1038/sj.leu.2401793 · Cited by 45
Self-citationCalcium/calmodulin-dependent protein kinases as potential targets in cancer therapy
Rodriguez–Mora, O., LaHair, M. M., Howe, C. J., McCubrey, J. A., & Franklin, R. A. (2005) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.9.4.791 · Cited by 39
Self-citationMNK, EIF4E and targeting translation for therapy
Silva, R. L. A., & Wendel, H. (2008) · Cell Cycle · doi:10.4161/cc.7.5.5486 · Cited by 38
Effects of inducible MEK1 activation on the cytokine dependency of lymphoid cells
Blalock, W. L., Pearce, M., Chang, F., Lee, J. T., Pohnert, S. C., Burrows, C., Steelman, L., Franklin, R. A., McMahon, M., & McCubrey, J. A. (2001) · Leukemia · doi:10.1038/sj.leu.2402109 · Cited by 36
Self-citationSynergy between Raf and BCL2 in abrogating the cytokine dependency of hematopoietic cells
Moye, P. W., Blalock, W. L., Hoyle, P., Chang, F., Franklin, R. A., Oppenheimer, C. W., Pearce, M., Steelman, L. S., McMahon, M., & McCubrey, J. A. (2000) · Leukemia · doi:10.1038/sj.leu.2401792 · Cited by 35
Self-citationMcCubrey, J. A., Steelman, L. S., Abrams, S. L., Chappell, W. H., Russo, S. M., Ove, R., Milella, M., Tafuri, A., Lunghi, P., Bonati, A., et al. (2009) · Expert Opinion on Emerging Drugs · doi:10.1517/14728210903232633 · Cited by 34
Self-citationLee, J. T., & McCubrey, J. A. (2002) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.6.6.659 · Cited by 33
Self-citationReactive Oxygen Intermediates and Signaling Through Kinase Pathways
McCubrey, J. A., & Franklin, R. A. (2006) · Antioxidants and Redox Signaling · doi:10.1089/ars.2006.8.1745 · Cited by 31
Self-citationvon Bubnoff, N. C. C., Gorantla, S. P., Engh, R. A., de Oliveira, T. M., Thöne, S., Åberg, E., Peschel, C., & Duyster, J. (2010) · Oncogene · doi:10.1038/onc.2010.476 · Cited by 31
Zebisch, A., Haller, M., Hiden, K., Goebel, T. E., Höefler, G., Troppmair, J., & Sill, H. (2009) · Leukemia · doi:10.1038/leu.2009.68 · Cited by 30
Christiansen, D. H., Desta, F., Andersen, M. K., & Pedersen-Bjergaard, J. (2007) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20426 · Cited by 26
BRAF mutations are very rare in B- and T-cell pediatric acute lymphoblastic leukemias
Davidsson, J., Lilljebjörn, H., Panagopoulos, I., Fioretos, T., & Johansson, B. (2008) · Leukemia · doi:10.1038/leu.2008.14 · Cited by 25
The T1790A BRAF mutation (L597Q) in childhood acute lymphoblastic leukemia is a functional oncogene
Hou, P., Liu, D., & Xing, M. (2007) · Leukemia · doi:10.1038/sj.leu.2404761 · Cited by 10
Haslam, K., Chadwick, N., Kelly, J., Browne, P., Vandenberghe, E., Flynn, C. M., Conneally, E., & Langabeer, S. E. (2010) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-010-0567-2 · Cited by 4
Cited by
Tumor biomarkers for diagnosis, prognosis and targeted therapy
Zhou, Y., Tao, L., Qiu, J., Xu, J., Yang, X., Zhang, Y., Tian, X., Guan, X., Cen, X., & Zhao, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01823-2 · Cited by 720
McCubrey, J. A., Steelman, L. S., Chappell, W. H., Abrams, S. L., Franklin, R. A., Montalto, G., Cervello, M., Libra, M., Candido, S., Malaponte, G., et al. (2012) · Oncotarget · doi:10.18632/oncotarget.659 · Cited by 314
Self-citationMcCubrey, J. A., Steelman, L. S., Bertrand, F. E., Davis, N. M., Abrams, S. L., Montalto, G., D'Assoro, A. B., Libra, M., Nicoletti, F., Maestro, R., et al. (2014) · Leukemia · doi:10.1038/leu.2013.184 · Cited by 255
Self-citationKnight, T., & Irving, J. A. E. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00160 · Cited by 164
Mammalian cells acquire epigenetic hallmarks of human cancer during immortalization
Tommasi, S., Zheng, A., Weninger, A., Bates, S. E., Li, X. A., Wu, X., Hollstein, M., & Besaratinia, A. (2013) · Nucleic Acids Research · doi:10.1093/nar/gks1051 · Cited by 45
Metadata
- Authors
- Steelman, L. S., Franklin, R. A., Abrams, S. L., Chappell, W., Kempf, C. R., Bäsecke, J., Stivala, F., Donia, M., Fagone, P., Nicoletti, F., Libra, M., Ruvolo, P., Ruvolo, V, Evangelisti, C., Martelli, A. M., & McCubrey, J. A.
- Venue
- Leukemia
- Published
- 2011-04-15
- Volume
- 25
- Issue
- 7
- Pages
- 1080-1094
- ISSN
- 0887-6924 (ISSN-L)
- 1476-5551
- OpenAlex
- W1596038553
- Cited by
- 261
- References
- 163
- FWCI
- 10.23
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.